B-cell directed therapies in antiphospholipid antibody syndrome - New directions based on murine and human data

Saakshi Khattri*, Gisele Zandman-Goddard, Elena Peeva

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

53 Scopus citations

Abstract

The increased awareness of the role of humoral immunophysiology in antiphospholipid syndrome (APS) has aroused interest in B cells as therapeutic targets in this disease. This paper reviews the literature on B cell directed therapies in human and experimental APS. The clinical data is limited to B cell depletion with rituximab and comprises case reports and case series. Murine studies include use of modulators of B cell function such as belimumab and abatacept. In both human and murine studies, B cell directed therapies appeared to have clinical and serologic beneficial effects including a decrease in the antiphospholipid antibody titers after treatment. Randomized controlled clinical trials are needed to determine whether B cell depletors and/or B cell modulators can be effective agents for treating patients with APS.

Original languageEnglish
Pages (from-to)717-722
Number of pages6
JournalAutoimmunity Reviews
Volume11
Issue number10
DOIs
StatePublished - Aug 2012
Externally publishedYes

Keywords

  • Anticardiolipin antibody (aCL)
  • Antiphospholipid antibodies (aPL)
  • Antiphospholipid syndrome (APS)
  • Beta 2 Glycoprotein I antibody (β2GPI)
  • Catastrophic antiphospholipid syndrome (CAPS)
  • Lupus anticoagulant (LAC)
  • Rituximab

Fingerprint

Dive into the research topics of 'B-cell directed therapies in antiphospholipid antibody syndrome - New directions based on murine and human data'. Together they form a unique fingerprint.

Cite this